196 related articles for article (PubMed ID: 26967642)
1. Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors.
Bernhard FP; Heinzel S; Binder G; Weber K; Apel A; Roeben B; Deuschle C; Maechtel M; Heger T; Nussbaum S; Gasser T; Maetzler W; Berg D
PLoS One; 2016; 11(3):e0150552. PubMed ID: 26967642
[TBL] [Abstract][Full Text] [Related]
2. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease.
Godau J; Herfurth M; Kattner B; Gasser T; Berg D
J Neurol Neurosurg Psychiatry; 2010 May; 81(5):536-8. PubMed ID: 20176597
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease.
Picillo M; Erro R; Santangelo G; Pivonello R; Longo K; Pivonello C; Vitale C; Amboni M; Moccia M; Colao A; Barone P; Pellecchia MT
J Neurol; 2013 Jul; 260(7):1724-30. PubMed ID: 23400497
[TBL] [Abstract][Full Text] [Related]
4. Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure.
Ghazi Sherbaf F; Mohajer B; Ashraf-Ganjouei A; Mojtahed Zadeh M; Javinani A; Sanjari Moghaddam H; Shirin Shandiz M; Aarabi MH
Front Endocrinol (Lausanne); 2018; 9():608. PubMed ID: 30450079
[No Abstract] [Full Text] [Related]
5. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Numao A; Suzuki K; Miyamoto M; Miyamoto T; Hirata K
Parkinsonism Relat Disord; 2014 Feb; 20(2):212-6. PubMed ID: 24280021
[TBL] [Abstract][Full Text] [Related]
6. Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease.
Picillo M; Pivonello R; Santangelo G; Pivonello C; Savastano R; Auriemma R; Amboni M; Scannapieco S; Pierro A; Colao A; Barone P; Pellecchia MT
PLoS One; 2017; 12(10):e0186508. PubMed ID: 29065116
[TBL] [Abstract][Full Text] [Related]
7. Correlation between serum IGF-1 and EGF levels and neuropsychiatric and cognitive in Parkinson's disease patients.
Shi X; Zheng J; Ma J; Li D; Gu Q; Chen S; Wang Z; Sun W; Li M
Neurol Sci; 2023 Mar; 44(3):881-887. PubMed ID: 36383265
[TBL] [Abstract][Full Text] [Related]
8. Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinson's disease.
Ma J; Jiang Q; Xu J; Sun Q; Qiao Y; Chen W; Wu Y; Wang Y; Xiao Q; Liu J; Tang H; Chen S
Dement Geriatr Cogn Disord; 2015; 39(5-6):251-6. PubMed ID: 25661865
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease.
Pellecchia MT; Santangelo G; Picillo M; Pivonello R; Longo K; Pivonello C; Vitale C; Amboni M; De Rosa A; Moccia M; Erro R; De Michele G; Santoro L; Colao A; Barone P
Eur J Neurol; 2014 May; 21(5):802-7. PubMed ID: 23551560
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor in Parkinson's disease is related to nonmotor symptoms and the volume of specific brain areas.
Shi X; Zheng J; Ma J; Wang Z; Sun W; Li M; Huang S; Hu S
Neurosci Lett; 2022 Jul; 783():136735. PubMed ID: 35709879
[TBL] [Abstract][Full Text] [Related]
11. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
[TBL] [Abstract][Full Text] [Related]
12. A longitudinal study of serum insulin-like growth factor-I levels over 6 years in a large cohort of children and adolescents with type 1 diabetes mellitus: A marker reflecting diabetic retinopathy.
Öberg D; Salemyr J; Örtqvist E; Juul A; Bang P
Pediatr Diabetes; 2018 Aug; 19(5):972-978. PubMed ID: 29663652
[TBL] [Abstract][Full Text] [Related]
13. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
[TBL] [Abstract][Full Text] [Related]
14. Serum insulin-like growth factor-1 and nitric oxide levels in Parkinson's disease.
Tuncel D; Inanc Tolun F; Toru I
Mediators Inflamm; 2009; 2009():132464. PubMed ID: 19300521
[TBL] [Abstract][Full Text] [Related]
15. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis.
Posavi M; Diaz-Ortiz M; Liu B; Swanson CR; Skrinak RT; Hernandez-Con P; Amado DA; Fullard M; Rick J; Siderowf A; Weintraub D; McCluskey L; Trojanowski JQ; Dewey RB; Huang X; Chen-Plotkin AS
PLoS Med; 2019 Oct; 16(10):e1002931. PubMed ID: 31603904
[TBL] [Abstract][Full Text] [Related]
17. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
[TBL] [Abstract][Full Text] [Related]
18. Serum Insulin-Like Growth Factor-1 in Patients with De Novo, Drug Naïve Parkinson's Disease: A Meta-Analysis.
Li DH; He YC; Quinn TJ; Liu J
PLoS One; 2015; 10(12):e0144755. PubMed ID: 26657015
[TBL] [Abstract][Full Text] [Related]
19. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
[TBL] [Abstract][Full Text] [Related]
20. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
